Table 2.
Quantitative analysis of CACNA1C splice variants in human heart left ventricle (n = 65) using fluorescently labeled primers or real-time PCR (labeled with #)
Locus | Splice variants | 65 samples measured individually |
Pooled sample from 65 heartsa |
Pooled sample from five normal heartsb |
Functional consequencea(ref) | |
---|---|---|---|---|---|---|
Mean ± SD (%) | Range % (min to max) | |||||
1# | E1a-E2 | 70 ± 7 | 47–87 | 67 | 71 | Activated by PKC [15] |
E1-E2 | 30 ± 7 | 13–53 | 33 | 29 | Inhibited by PKC [15] | |
2 | E2-E3 | 99.9 ± 0.1 | 99–100 | 100 | 100 | |
E2-E3 + 4nt | 0.04 ± 0.10 | 0–1 | 0 | 0 | Frame shift | |
3 | E6-E7 | 50 ± 3 | 40–59 | 52 | 53 | |
E6-E7-12nt | 50 ± 3 | 41–60 | 48 | 47 | ||
4a | E7-E8/E8a-E9-E10 | 99 ± 1 | 91–100 | 95 | 96 | |
E7-E9-E10 | 1 ± 1 | 0–9 | 3 | 3 | ||
E7-E10 | 0 | 0 | 2 | 1 | ||
4b# | E7-E8 | 26 ± 12 | 13–91 | 25 | 15 | Smooth muscle isoform, higher affinity for DHP [18] |
E7-E8a | 74 ± 12 | 9–87 | 75 | 85 | Cardiac isoform, lower affinity for DHP [18] |
|
5 | E9-E10 | 98 ± 1 | 94–99 | 97 | 96 | |
E9-E9*-E10 | 2 ± 1 | 0.6–6 | 3 | 4 | ||
6 | E10-E11 | 99.0 ± 0.4 | 97–100 | 99 | 99 | |
E10-E10*-E11 | 1.0 ± 0.5 | 0–3 | 1 | 1 | ||
7 | E14-E15 | 75 ± 4 | 60–83 | 75 | 78 | |
E14-E15-73nt | 25 ± 4 | 17–40 | 25 | 22 | Frame shift, hemi-channel [11] | |
8 | E16-E17 | 99.0 ± 0.4 | 98–99 | 96 | 97 | |
E16-E17 + 9nt | 1 ± 0.4 | 0.2–2.3 | 4 | 3 | ||
E16-E17 + 12nt | 0.2 ± 0.2 | 0–1 | 0.2 | 0.2 | ||
9a | E20-E21/22-E23 | 99.0 ± 0.6 | 97–100 | 98 | 98 | |
E20-E23 | 1.0 ± 0.6 | 0–2 | 2 | 2 | ||
9b# | E20-E21 | 91 ± 2 | 81–94 | 89 | 87 | |
E20-E22 | 9 ± 2 | 6–19 | 11 | 13 | More sensitive to DHP [14] | |
10a | E30-E34 | 0.2 ± 0.4 | 0–2 | 0.3 | 0.2 | Nonfunctional channel [11] |
E30-E33-E34 | 2 ± 1 | 1–7 | 1 | 0.6 | ||
E30-E31-E32-E34 | 1 ± 0.2 | 0–1 | 0.5 | 0.5 | ||
E30-E31-E32-6nt-E34 | 0.03 ± 0.06 | 0–0.3 | 0 | 0 | ||
E30-E31-E32-E33-E34 | 1.0 ± 0.5 | 0.3–3 | 1.00 | 1 | ||
E30-E31-E32-6nt-E33-E34 | 0.2 ± 0.2 | 0–1 | 0 | 0.2 | ||
E30-E31/E32-E33-E34 | 48 ± 8 | 16–63 | 50 | 42 | Reference isoform [11] | |
E30-E32-6nt-E34 | 3 ± 1 | 1–6 | 3 | 2.9 | A isoform, Change gating property [11] |
|
E30-E32-6nt-E33-E34 | 15 ± 2 | 11–26 | 10 | 20 | B isoform, | |
E30-E31/E32-E34 | 24 ± 6 | 9–41 | 34 | 32 | C isoform | |
10b# | E30-E31 | 13 ± 6 | 5–33 | 20 | 19 | Fetal isoform [19] |
E30-E32 | 87 ± 6 | 67–95 | 80 | 81 | Adult isoform [19] | |
11 | E40-E41 | 96 ± 1 | 93–98 | 93 | 92 | |
E40-E41 + 57nt | 4 ± 1 | 2–7 | 7 | 8 | Change gating property [13] | |
12 | E44-E46 | 99 ± 3 | 90–100 | 99 | 98 | |
E44-E45*-E46 | 1 ± 3 | 0–9 | 1 | 2 | ||
E44-E45-E46 | 0 | 0 | 0 | 0 | ||
E44-E45*-187nt-E46 | 0 | 0 | 0 | 0 |
Data represent the percentage of each splice variant of the total transcripts in each locus. Data are the mean ± SD of 65 samples, each was measured twice. PKC, protein kinase C; DHP, dihydropyridine.
Same amounts of cDNA from 65 heart tissues were pooled, and splice variants measured twice and the average was shown.
Same amounts of total RNA from five normal heart left ventricles were pooled, then the cDNA synthesized and the splice variants measured. Data are the average of two cDNA preparations.